Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | GVAX + unspecified PD-1 antibody |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| GVAX | GVAX is a cancer vaccine derived from irradiated autologous or allogeneic tumor cells engineered to secrete GM-CSF, which potentially stimulates anti-tumor immune response (PMID: 16026242). | |||
| unspecified PD-1 antibody | Experimental PD-1 antibody | Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 134 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| B2M del | melanoma | resistant | GVAX + unspecified PD-1 antibody | Preclinical | Actionable | In a preclinical study, GVAX in combination with an anti-PD1 treatment did not inhibit tumor growth or increase survival in a syngeneic mouse model of melanoma harboring B2M deletion (PMID: 30559380). | 30559380 |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|